Since higher SMN2 copy numbers are associated with reduced disease severity in SMA patients, most therapeutic efforts have focused on increasing expression of SMN through modulation of SMN2 splicing or SMN replacement by gene therapy [5–8]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.